British drugmaker GlaxoSmithKline Plc is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) to contribute towards the effort of developing a vaccine for the coronavirus outbreak, GSK and CEPI said. GSK will make its “adjuvant platform technology” available for developing a vaccine against the 2019-nCoV virus, according to the statement.
GSK to collaborate with CEPI in effort to develop coronavirus vaccine
Date posted: Monday 3 February 2020